Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PLUR)

Pluristem Therapeutics CEO Issues Shareholder Update

GlobeNewswire February 10, 2020

In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.

GlobeNewswire February 3, 2020

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

GlobeNewswire December 17, 2019

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

GlobeNewswire December 3, 2019

Pluristem Therapeutics CEO Issues Shareholder Update

GlobeNewswire November 12, 2019

RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare

GlobeNewswire November 4, 2019

Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

GlobeNewswire September 16, 2019

Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

GlobeNewswire September 9, 2019

Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

GlobeNewswire August 21, 2019

Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome

GlobeNewswire July 31, 2019

Pluristem Therapeutics' CEO Issues Shareholders Update

GlobeNewswire July 24, 2019

Pluristem Announces One-for-Ten Reverse Split of its Common Shares

GlobeNewswire July 24, 2019

Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN

GlobeNewswire July 17, 2019

Pluristem Therapeutics' CEO Issues Shareholder Letter

GlobeNewswire July 2, 2019

Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board

GlobeNewswire June 24, 2019

Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product

GlobeNewswire June 17, 2019

Lead Physicians in Pluristem's Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper

GlobeNewswire May 15, 2019

Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry

GlobeNewswire May 6, 2019

Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe

GlobeNewswire April 29, 2019

Pluristem Therapeutics Issues Shareholder Update

GlobeNewswire April 23, 2019